Lumacaftor Plus Ivacaftor Combination + Ivacaftor
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Conditions
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Trial Timeline
Oct 1, 2013 → Apr 1, 2016
NCT ID
NCT01931839About Lumacaftor Plus Ivacaftor Combination + Ivacaftor
Lumacaftor Plus Ivacaftor Combination + Ivacaftor is a phase 3 stage product being developed by Vertex Pharmaceuticals for Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT01931839. Target conditions include Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01931839 | Phase 3 | Completed |
Competing Products
20 competing products in Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation